Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

Pour: IACM Médical

The plant cannabinoid THCV (tetrahydrocannabivarin) decreases glucose levels and may have further beneficial effects in patients with type 2 diabetes. This is the result of research by scientists from Nottingham, London and Oxford in the UK, published in Diabetes Care. They included 62 patients with noninsulin-treated type 2 diabetes in a placebo-controlled study with CBD (100 mg twice daily), THCV (5 mg twice daily), a combination of CBD and THCV (5 mg of both cannabinoids twice daily), and a 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily).

Compared with placebo, THCV significantly decreased fasting plasma glucose and improved the function of cells in the pancreas, which are responsible for insulin production (HOMA2 beta-cell function). It also improved the values for adiponectin and apolipoprotein A. There was no difference between CBD and placebo. None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated. Authors concluded that “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Check the study here.

Source: http://www.cannabis-med.org/english/bulletin/iacm.php

Kannabia Seed Company vend à ses clients un produit de collection, un souvenir. Nous ne pouvons pas et ne devons pas donner de conseils de culture car notre produit n’est pas destiné à cet usage.

Nous ne sommes pas responsables de l’utilisation illicite qui pourrait être faite par des tiers des informations publiées ici. La culture du cannabis pour l’autoconsommation est une activité soumise à certaines restrictions légales qui varient d’un État à l’autre. Nous recommandons de revoir la législation en vigueur dans le pays de résidence pour éviter d’encourir l’exercice d’une activité illégale.